Research and Markets: Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/dfd4xk/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Kowa Company, Ltd.
  • Antisense Therapeutics Limited
  • BioDiem Ltd
  • Regeneron Pharmaceuticals, Inc.
  • R-Tech Ueno, Ltd.
  • Paloma Pharmaceuticals, Inc.
  • Acucela Inc.
  • Gene Signal International SA
  • Promedior, Inc.
  • Inotek Pharmaceuticals Corporation
  • Angstrom Pharmaceuticals, Inc.
  • Stemedica Cell Technologies, Inc.
  • Dimerix Bioscience Pty Ltd
  • Resolvyx Pharmaceuticals, Inc
  • Charlesson LLC.
  • MacuCLEAR, Inc.
  • Stelic Institute & Co.
  • EyeCyte, Inc.
  • Vascular Pharmaceuticals, Inc.
  • PanOptica, Inc.
  • EyeGene, Inc.
  • Targazyme, Inc.
  • Aprogen, Inc.
  • MingSight Pharmaceuticals
  • Bionure Farma, S.L.
  • Islet Sciences, Inc.
  • Foresee Pharmaceuticals, LLC
  • Biomar Microbial Technologies

Drug Profiles

  • aflibercept (recombinant)
  • ripasudil
  • AKB-9778
  • ATL-1103
  • DG-3173
  • emixustat hydrochloride
  • aganirsen
  • GLY-230
  • EG-Mirotin
  • Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders
  • DT-23552
  • RX-20001
  • A-6
  • P-529
  • BDM-E
  • RTU-007
  • Mesenchymal Stem Cells
  • PRM-167
  • A-717
  • MS-553
  • PAN-90806
  • MC-4001
  • AP-202
  • FP-002
  • Recombinant Protein for Cancer and Diabetic Retinopathy
  • Cyndacel-M
  • VPI-2690-B
  • Small Molecule for Diabetic Neuropathy and Retinopathy
  • TZ-101
  • V-1932

For more information visit http://www.researchandmarkets.com/research/dfd4xk/diabetic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals